A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2016
Price : $35 *
At a glance
- Drugs Sotatercept (Primary)
- Indications Bone disorders; Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 30 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 22 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 02 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record